The pathobiology of polycystic kidney disease from a metabolic viewpoint
The pathobiology of polycystic kidney disease from a metabolic viewpoint
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Autosomal dominant polycystic kidney disease (ADPKD) affects an estimated 1 in 1,000 people and slowly progresses to end-stage renal disease (ESRD) in about half of these individuals. Tolvaptan, a vasopressin 2 receptor blocker, has been approved by regulatory authorities in many countries as a therapy to slow cyst growth, but additional treatments...
Alternative Titles
Full title
The pathobiology of polycystic kidney disease from a metabolic viewpoint
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2286939483
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2286939483
Other Identifiers
ISSN
1759-5061
E-ISSN
1759-507X
DOI
10.1038/s41581-019-0183-y
